Nestibil (Bilastine)

Bilastine, the active ingredient in Nestibil, is a second‑generation H1 antihistamine presented as an oral dosage form for oral use. It treats allergic rhinitis and chronic urticaria in adults and adolescents.

GNH USA supplies Nestibil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bilastine is used to manage allergic conditions mediated by histamine release.

- Seasonal allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. - Perennial allergic rhinitis: alleviates year‑round nasal symptoms caused by environmental allergens. - Chronic idiopathic urticaria: diminishes wheals and itching, improving quality of life.

Bilastine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: transient sensation of oral dryness. - Fatigue: occasional feeling of tiredness. - Nausea: mild gastrointestinal upset. - Dizziness: brief episodes, usually self‑limiting.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare severe skin eruption. - Cardiac arrhythmia: very uncommon but reported in isolated cases. - Hepatic injury: rare elevation of liver enzymes. - Severe hypersensitivity: rash, swelling, or bronchospasm.

Before initiating therapy, consider the following safety measures.

- Renal function assessment: adjust use in severe renal impairment. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant strong P‑gp inhibitors: monitor for increased exposure. - Known hypersensitivity: avoid if patient has previous allergic reaction to bilastine or excipients. - Pregnancy and lactation: evaluate risk‑benefit as data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Bilastine may interact with other medicines that affect its absorption or transport.

Major Interactions (Avoid): - Strong P‑glycoprotein inhibitors (e.g., ketoconazole, erythromycin): may raise bilastine plasma levels. - Antacids containing aluminum or magnesium: can markedly reduce oral absorption.

Moderate Interactions (Monitor Closely):\n- Alcohol: may enhance sedation despite bilastine’s low sedative profile. - Other antihistamines: additive antihistaminic effect may increase drowsiness. - CYP3A4 inducers (e.g., rifampicin): could lower exposure, potentially reducing efficacy.